Mark D. Kaufmann, MD, FAAD
SESSIONS
DISCLOSURES
Almirall – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Biofrontera – Consultant (1099 relationship)(Fees); Botanix Pharmaceuticals – Advisory Board(Fees); DermTech Inc. – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Incyte – Consultant (1099 relationship)(Fees); MoleSafe, Inc. – Other(Stock); Novartis – Consultant (1099 relationship)(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pelthos Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB Pharma – Consultant (1099 relationship)(Fees); VeraDermics Inc. – Advisory Board(Fees); Verrica Pharmaceuticals Inc – Consultant (1099 relationship)(Fees);